Generic Tazarotene Cream, 0.05% for the Treatment of Plaque Psoriasis
Status:
Completed
Trial end date:
2016-05-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to compare the safety and efficacy profiles of Tazarotene Cream,
0.05% and Tazorac® (Tazarotene) Cream, 0.05% in order to demonstrate bioequivalence and to
demonstrate the superiority of the 2 active creams over that of the Vehicle (placebo) in the
treatment of plaque psoriasis.